Here is something from today:
VASOMEDICAL ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN ITS
CONTROLLED MULTICENTER STUDY WITH EECP BUSINESS/MEDICAL EDITORS
WESTBURY, N.Y.--(BW HEALTHWIRE)--MAY 5, 1997--VASOMEDICAL INC.
patient enrollment in its Controlled Multicenter Study with EECP Business/Medical Editors
WESTBURY, N.Y.--(BW HealthWire)--May 5, 1997--Vasomedical Inc. (NASDAQ:VASO) has announced the
completion of patient enrollment in the Multicenter Study of Enhanced External Counterpulsation (MUST -- EECP), a
company-sponsored controlled, double-blinded clinical study of EECP(R) in the treatment of patients with coronary
artery disease and chronic angina pectoris. More than 120 patients were randomized to active counterpulsation or
inactive (sham) counterpulsation for 35 hours of outpatient therapy over a 4-7 week period.
"We are very happy that the recruitment target of 120 patients has been exceeded," said Anthony Viscusi, president and
CEO of the company. He continued, "We look forward to the unblinding of the study and to results that will further
validate EECP(R) as a safe and effective treatment of patients with coronary artery disease and make it possible for
EECP(R) to find a central place in mainstream medicine as a noninvasive treatment option." Speaking on behalf of the
MUST-EECP investigators, Dr. Peter F. Cohn, professor of Medicine and Chief of Cardiology at the State University of
New York at Stony Brook, remarked that "the completion of patient enrollment is a noteworthy accomplishment and an
important milestone in the history of external counterpulsation. Now that patient enrollment is completed, we look
forward to the unblinding and publication of the findings in a widely read peer-reviewed medical journal soon after
presentation of study results at a major medical meeting."
Institutions participating in MUST-EECP are: University of California San Francisco, Colombian University College of
Physicians & Surgeons at the Columbia-Presbyterian Medical Center in New York, Beth Israel-Deaconess Hospital, a
teaching affiliate of Harvard Medical School, Yale University School of Medicine, Grant/Riverside Methodist Hospitals in
Columbus, Ohio, University of Pittsburgh Medical Center, and Loyola University Medical Center in Chicago. EECP(R),
which received market clearance from the FDA in 1995, is believed by the company to be presently the only clinically
tested noninvasive outpatient procedure to relieve angina pectoris by improving perfusion of insufficiently supplied areas
of the heart. Angina pectoris affects more than seven million people in the United States.
People suffering with angina pectoris may receive EECP(R) at hospitals and clinics throughout the country. Vasomedical
Inc. provides equipment, staff training, and treatment guidelines for EECP(R). Vasomedical is a medical technology
company devoted to the development, manufacture and commercialization of innovative and cost-effective cardiovascular
products.
Copyright 1997, Business Wire. All of the releases provided by Business Wire are protected by copyright and other applicable laws, treaties and conventions. Information contained
in the releases is furnished by Business Wire's members, who are solely responsible for their content, accuracy and originality. All reproduction, other than for an individual user's
reference, is prohibited without prior written permission.
nasdaq! |
